{"id":4842,"date":"2026-03-17T00:13:11","date_gmt":"2026-03-16T23:13:11","guid":{"rendered":"https:\/\/www.unioviedo.es\/IUOPA\/?p=4842"},"modified":"2026-03-17T00:44:10","modified_gmt":"2026-03-16T23:44:10","slug":"clinical-trial-early-nivolumab-addition-to-regorafenib-in-patients-with-hepatocellular-carcinoma-in-second-line-the-going-trial-2","status":"publish","type":"post","link":"https:\/\/www.unioviedo.es\/IUOPA\/en\/clinical-trial-early-nivolumab-addition-to-regorafenib-in-patients-with-hepatocellular-carcinoma-in-second-line-the-going-trial-2\/","title":{"rendered":"Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-justify-content-center\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><style type=\"text\/css\">@media only screen and (max-width:1024px) {.fusion-title.fusion-title-1{margin-top:0px!important; margin-right:0px!important;margin-bottom:20px!important;margin-left:0px!important;}}@media only screen and (max-width:640px) {.fusion-title.fusion-title-1{margin-top:0px!important; margin-right:0px!important;margin-bottom:20px!important; margin-left:0px!important;}}<\/style><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-one\" style=\"font-size:30px;margin-top:0px;margin-right:0px;margin-bottom:20px;margin-left:0px;\"><h1 class=\"title-heading-left fusion-responsive-typography-calculated\" style=\"margin:0;font-size:1em;--fontSize:30;line-height:1.1;\">Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)<\/h1><\/div><div ><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-zoomin\"><a href=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2026\/03\/PSTOLOGIA-QUIRURGICA-ABDOMINAL.png\" class=\"fusion-lightbox\" data-rel=\"iLightbox[ab7bb4e370a8329a87d]\" data-title=\"PSTOLOGIA QUIRURGICA ABDOMINAL\" title=\"PSTOLOGIA QUIRURGICA ABDOMINAL\"><img decoding=\"async\" width=\"2560\" height=\"1443\" src=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2026\/03\/PSTOLOGIA-QUIRURGICA-ABDOMINAL.png\" data-orig-src=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2026\/03\/PSTOLOGIA-QUIRURGICA-ABDOMINAL.png\" alt class=\"lazyload img-responsive wp-image-4825\" srcset=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%272560%27%20height%3D%271443%27%20viewBox%3D%270%200%202560%201443%27%3E%3Crect%20width%3D%272560%27%20height%3D%271443%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-srcset=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2026\/03\/PSTOLOGIA-QUIRURGICA-ABDOMINAL-200x113.png 200w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2026\/03\/PSTOLOGIA-QUIRURGICA-ABDOMINAL-400x225.png 400w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2026\/03\/PSTOLOGIA-QUIRURGICA-ABDOMINAL-600x338.png 600w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2026\/03\/PSTOLOGIA-QUIRURGICA-ABDOMINAL-800x451.png 800w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2026\/03\/PSTOLOGIA-QUIRURGICA-ABDOMINAL-1200x676.png 1200w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2026\/03\/PSTOLOGIA-QUIRURGICA-ABDOMINAL.png 2560w\" data-sizes=\"auto\" data-orig-sizes=\"(max-width: 1024px) 100vw, (max-width: 640px) 100vw, 1200px\" \/><\/a><\/span><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><div class=\"fusion-text fusion-text-1\"><h5>Sanduzzi-Zamparelli M, Matilla A, Lledo JL, Mu\u00f1oz-Mart\u00ednez S, Varela M, I\u00f1arrairaegui M, Perell\u00f3 C, M\u00ednguez B, Llarch N, M\u00e1rquez L, Guerrero A, Iserte G, Casta\u00f1o-Garc\u00eda A, Carri\u00f3n L, Fortuny M, Rimola J, Garc\u00eda-Criado \u00c1, Domenech G, Torres F, Rios- Guillermo J, Boix L, Samper E, Kateb \u00c0, Bruix J, Reig M.<\/h5>\n<h6>Aliment Pharmacol Ther. 2026 Feb 23. doi: 10.1111\/apt.70578. Online ahead of print.<\/h6>\n<h6>PMID:\u00a041725391<\/h6>\n<\/div><div class=\"fusion-text fusion-text-2\"><p>The journal <strong data-start=\"12\" data-end=\"92\">National Library of Medicine (National Center for Biotechnology Information)<\/strong> has highlighted the work of the <strong data-start=\"125\" data-end=\"163\">Abdominal Surgical Pathology Group<\/strong>, with the participation of <strong>Mar\u00eda Varela Calvo\u00a0<\/strong>(<a href=\"mailto:varelacmaria@uniovi.es\"><strong>varelacmaria@uniovi.es<\/strong><\/a>).<\/p>\n<p><b>Check the publication at the following \u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41725391\/\" target=\"_blank\" rel=\"noopener\">link<\/a><\/b><\/p>\n<\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-0{width:75% !important;order : 0;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 2.56%;margin-left : 2.56%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;order : 0;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 0px;margin-top : 0px;padding-right : 30px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 30px;}@media only screen and (max-width:1024px) {.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 80px;}}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 20px 0px 20px 0px;\"><div class=\"fusion-sharing-box fusion-sharing-box-1\" style=\"background-color:#f6f6f6;margin-top:60px;\" data-title=\"Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)\" data-description=\"Sanduzzi-Zamparelli M, Matilla A, Lledo JL, Mu\u00f1oz-Mart\u00ednez S, Varela M, I\u00f1arrairaegui M, Perell\u00f3 C, M\u00ednguez B, Llarch N, M\u00e1rquez L, Guerrero A, Iserte G, Casta\u00f1o-Garc\u00eda A, Carri\u00f3n L, Fortuny M, Rimola J, Garc\u00eda-Criado \u00c1, Domenech G, Torres F, Rios- Guillermo J, Boix L, Samper E, Kateb \u00c0, Bruix J, Reig M.\r\nAliment Pharmacol Ther.\" data-link=\"https:\/\/www.unioviedo.es\/IUOPA\/en\/clinical-trial-early-nivolumab-addition-to-regorafenib-in-patients-with-hepatocellular-carcinoma-in-second-line-the-going-trial-2\/\"><h4 class=\"tagline\" style=\"color:#2f2f2f;\">Compartir noticia<\/h4><div class=\"fusion-social-networks sharingbox-shortcode-icon-wrapper sharingbox-shortcode-icon-wrapper-1\"><span><a href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.unioviedo.es%2FIUOPA%2Fen%2Fclinical-trial-early-nivolumab-addition-to-regorafenib-in-patients-with-hepatocellular-carcinoma-in-second-line-the-going-trial-2%2F&amp;t=Clinical%20Trial%3A%20Early%20Nivolumab%20Addition%20to%20Regorafenib%20in%20Patients%20With%20Hepatocellular%20Carcinoma%20in%20Second-Line%20%28The%20GOING%20Trial%29\" target=\"_blank\" rel=\"noreferrer\" title=\"Facebook\" aria-label=\"Facebook\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-facebook awb-icon-facebook\" style=\"color:#76b5ae;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/twitter.com\/share?text=Clinical%20Trial%3A%20Early%20Nivolumab%20Addition%20to%20Regorafenib%20in%20Patients%20With%20Hepatocellular%20Carcinoma%20in%20Second-Line%20%28The%20GOING%20Trial%29&amp;url=https%3A%2F%2Fwww.unioviedo.es%2FIUOPA%2Fen%2Fclinical-trial-early-nivolumab-addition-to-regorafenib-in-patients-with-hepatocellular-carcinoma-in-second-line-the-going-trial-2%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Twitter\" aria-label=\"Twitter\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-twitter awb-icon-twitter\" style=\"color:#76b5ae;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/www.linkedin.com\/shareArticle?mini=true&amp;url=https%3A%2F%2Fwww.unioviedo.es%2FIUOPA%2Fen%2Fclinical-trial-early-nivolumab-addition-to-regorafenib-in-patients-with-hepatocellular-carcinoma-in-second-line-the-going-trial-2%2F&amp;title=Clinical%20Trial%3A%20Early%20Nivolumab%20Addition%20to%20Regorafenib%20in%20Patients%20With%20Hepatocellular%20Carcinoma%20in%20Second-Line%20%28The%20GOING%20Trial%29&amp;summary=Sanduzzi-Zamparelli%20M%2C%20Matilla%20A%2C%20Lledo%20JL%2C%20Mu%C3%B1oz-Mart%C3%ADnez%20S%2C%20Varela%20M%2C%20I%C3%B1arrairaegui%20M%2C%20Perell%C3%B3%20C%2C%20M%C3%ADnguez%20B%2C%20Llarch%20N%2C%20M%C3%A1rquez%20L%2C%20Guerrero%20A%2C%20Iserte%20G%2C%20Casta%C3%B1o-Garc%C3%ADa%20A%2C%20Carri%C3%B3n%20L%2C%20Fortuny%20M%2C%20Rimola%20J%2C%20Garc%C3%ADa-Criado%20%C3%81%2C%20Domenech%20G%2C%20Torres%20F%2C%20Rios-%20Guillermo%20J%2C%20Boix%20L%2C%20Samper%20E%2C%20Kateb%20%C3%80%2C%20Bruix%20J%2C%20Reig%20M.%0D%0AAliment%20Pharmacol%20Ther.\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"LinkedIn\" aria-label=\"LinkedIn\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-linkedin awb-icon-linkedin\" style=\"color:#76b5ae;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"mailto:?subject=Clinical%20Trial%3A%20Early%20Nivolumab%20Addition%20to%20Regorafenib%20in%20Patients%20With%20Hepatocellular%20Carcinoma%20in%20Second-Line%20%28The%20GOING%20Trial%29&amp;body=https%3A%2F%2Fwww.unioviedo.es%2FIUOPA%2Fen%2Fclinical-trial-early-nivolumab-addition-to-regorafenib-in-patients-with-hepatocellular-carcinoma-in-second-line-the-going-trial-2%2F\" target=\"_self\" title=\"Correo electr\u00f3nico\" aria-label=\"Correo electr\u00f3nico\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-mail awb-icon-mail\" style=\"color:#76b5ae;\" aria-hidden=\"true\"><\/i><\/a><\/span><\/div><\/div><style type=\"text\/css\">.fusion-sharing-box-1 h4{margin-bottom:0 !important;}.fusion-sharing-box-1{flex-direction:row !important;padding-top:20px !important;padding-bottom:20px !important;}.sharingbox-shortcode-icon-wrapper-1 span.sharingbox-shortcode-icon-separator{border-right-width:0px !important;}@media only screen and (max-width:1024px){.fusion-sharing-box-1 h4{margin-right:0.5em !important;margin-bottom:0 !important;}.sharingbox-shortcode-icon-wrapper-1{width:auto !important;justify-content:flex-end !important;}.fusion-sharing-box-1{align-items:center !important;} }@media only screen and (max-width:640px){.fusion-sharing-box-1{flex-direction: column !important;align-items:center !important;}.fusion-sharing-box-1 h4{margin-bottom:revert !important;}.sharingbox-shortcode-icon-wrapper-1{width:100% !important;justify-content:space-between !important;} }<\/style><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-1{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-1 > .fusion-column-wrapper {padding-top : 20px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 20px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-2{ padding-top : 0px;margin-top : 0px;padding-right : 30px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 30px;}<\/style><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":4825,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[243,82],"tags":[162,168,157,521,519],"class_list":["post-4842","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-last-news-en","category-publications","tag-actualidad-iuopa-en","tag-asociaciones-contra-el-cancer-en","tag-avances-investigacion-en","tag-onchology","tag-research"],"_links":{"self":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/posts\/4842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/comments?post=4842"}],"version-history":[{"count":2,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/posts\/4842\/revisions"}],"predecessor-version":[{"id":4849,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/posts\/4842\/revisions\/4849"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/media\/4825"}],"wp:attachment":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/media?parent=4842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/categories?post=4842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/tags?post=4842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}